Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
m |
|||
| Line 13: | Line 13: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
| − | [[Category:Esophageal cancer medications]] | + | [[Category:Esophageal cancer medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 01:53, 1 May 2022
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Preliminary data
Esophageal squamous cell carcinoma
- RATIONALE 302: NCT03430843
Also known as
- Code name: BGB-A317